A one-time injection of ABBV-RGX-314, a gene therapy for wet age-related macular degeneration, yielded reductions in treatment burden and strong visual acuity maintenance at 5 years with no new safety signals, according to a speaker.
At the American Society of Retina Specialists annual meeting, Robert L. Avery, MD, of California Retina Consultants, presented long-term follow-up data on the RGX-314-001 phase 1/2a study that looked at five dosing levels of ABBV-RGX-314 (sura-vec, Regenxbio, AbbVie) in 37 patients who were enrolled into five cohorts. The primary endpoint was safety assessments